---
schema_version: "secwatch.filing_event.v1"
accession: "0001125345-23-000109"
form_type: "8-K"
ticker: "MGNX"
cik: "0001125345"
company_name: "MACROGENICS INC"
filed_at: "2023-08-09T23:59:59+00:00"
generated_at: "2026-06-11T21:24:41.330229+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# MacroGenics Q2 net income $57.5M on royalty gain; $50M TZIELD milestone from Sanofi

## Summary
- Net income of $57.5M ($0.92 diluted EPS) vs net loss of $41.3M a year ago; driven by $100.9M gain on royalty monetization.
- Total revenue $13.1M, down from $26.0M YoY; collaborative revenue fell to $6.0M from $16.9M.
- Cash $240.3M; plus $50M Sanofi milestone; cash runway extends into 2026.
- Pipeline: TAMARACK Phase 2 for vobra duo in mCRPC enrolling under amended protocol; lorigerlimab Phase 2 to start.
- Received $50M milestone from Sanofi after positive TZIELD Phase 3 data; additional $50M possible if net sales threshold met.

## SEC filing metadata
- accession: 0001125345-23-000109
- form_type: 8-K
- ticker: MGNX
- cik: 0001125345
- company_name: MACROGENICS INC
- filed_at: 2023-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1125345/000112534523000109/0001125345-23-000109-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1125345/000112534523000109/mgnx-20230809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001125345-23-000109
- JSON: https://secwatch.observer/filing/0001125345-23-000109.json
- Plain text: https://secwatch.observer/filing/0001125345-23-000109.txt

## Key facts
- Earnings Releases
  MACROGENICS INC reported the quarter ended June 30, 2023 results: revenue $13.1 million.
  - Period: the quarter ended June 30, 2023
  - Revenue: $13.1 million
  - Result: reported results
  source text: Total revenue was $13.1 million for the quarter ended June 30, 2023, compared to total revenue of $26.0 million for the quarter ended June 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1125345/000112534523000109/0001125345-23-000109-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.